Christine Helena Attenhofer Jost

Prof. Christine Helena Attenhofer Jost

HerzGefässZentrum Im Park, Hirslanden Klinik Im Park, Zürich, Switzerland
orcid
Fight for your dreams, and your dreams will fight for you
avatar
Co-authors
avatar
Following
avatar
Followers

Research Focus & Metrics

Explore full metrics on Scilit

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BBBujana Batusha-Sopi
Bujana Batusha-Sopi
KYKeiko Yonekawa
Keiko Yonekawa
SRStefan Russmann
Stefan Russmann
JBJasminka Bernheim
Jasminka Bernheim
SCStefano Caselli
Stefano Caselli
Christine Helena Attenhofer JostChristine Helena Attenhofer Jost
Christine Helena Attenhofer Jost
Background/Objectives: Venlafaxine (VEN) is a serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressant. Arterial hypertension (HTN), heart failure (HF), and arrhythmias are side effects of VEN. Cardiotoxicity (CTOX) as a feature of VEN-associated side-effects has only rarely been described. Methods: We conducted a search of our database for cases of VEN-associated CTOX, analyzing symptoms, echocardiographic findings, and laboratory results. Results: We identified five patients (three females, two males) with VEN-associated CTOX, aged 51 to 87 years at presentation. VEN dose was 150 and 375 mg daily and treatment duration was 1.5 to 15 years. Presenting features were HTN in three, “hypertrophic cardiomyopathy” in two, heart failure in three, and atrial fibrillation in three patients. Symptoms and signs of CTOX were reversible in all patients after discontinuation or dose reduction of VEN, suggesting a causal relationship between VEN and CTOX. Conclusions: VEN-associated CTOX can occur and progress to severe cardiomyopathy or heart failure. Potential risk factors include cardiac sympathetic stimulation, high VEN dosage, and prolonged treatment duration; however, CTOX may also occur at standard doses. Therefore, patients taking VEN should be routinely monitored for signs of cardiotoxicity, including monitoring of serum concentrations of VEN.
1
19 February 2018 in Trends in Cardiovascular Medicine
Verified
Journal Article
Closed access
PDF file
MGMatthias Greutmann
Matthias Greutmann
EBEmanuela R. Valsangiacomo Buechel
Emanuela R. Valsangiacomo Buechel
Christine Helena Attenhofer JostChristine Helena Attenhofer Jost
Christine Helena Attenhofer Jost
1
1 June 2026
Verified
Journal Article
Closed access
LWLeonard Weishaupt
Leonard Weishaupt
Christine Helena Attenhofer JostChristine Helena Attenhofer Jost
Christine Helena Attenhofer Jost
RBRonny R Buechel
Ronny R Buechel
SCStefano Caselli
Stefano Caselli
SSSarah Spalinger
Sarah Spalinger
CSChristian Schmied
Christian Schmied
1
3 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AYAdel Younes
Adel Younes
Christine Helena Attenhofer JostChristine Helena Attenhofer Jost
Christine Helena Attenhofer Jost
SGSteffen Glökler
Steffen Glökler
SCStefano Caselli
Stefano Caselli
SVSilvan Vesenbeckh
Silvan Vesenbeckh
MGMarco Giacchi
Marco Giacchi
Coronary artery fistulas (CAFs) are a rare, typically congenital coronary anomaly. They may cause myocardial ischemia through a coronary steal phenomenon. Acquired CAFs are exceptionally uncommon and are usually due to an intervention or trauma. We re-port the case of a 79-year-old man with history of clear cell renal cell carcinoma previ-ously treated with right nephrectomy in 2015. Seven years later, he underwent percu-taneous coronary intervention of severe LAD stenosis following out-of-hospital cardi-ac arrest. During follow-up, progressive exertional dyspnea and inducible lateral is-chemia led to repeated coronary angiography 15 months later revealing fistulous communications from the circumflex and right coronary arteries draining into a left pulmonary mass. Right-heart catheterization showed a small left-to-right shunt at rest (Qp/Qs 1.3). Thoracic computed tomography and biopsy confirmed a large pulmonary metastasis from clear cell renal cell carcinoma, suggesting that the fistulas developed as part of tumor angiogenesis. Transcatheter coil embolization would have been a strategy to reduce tumor perfusion and the coronary steal; however, we just limited our treatment to the tyrosine kinase inhibitor Axitinib due to the metastatic disease. This case describes a rare mechanism of acquired CAF formation in metastatic renal cell carcinoma.
1 August 2018 in Praxis
Verified
Journal Article
Closed access
Christine Helena Attenhofer JostChristine Helena Attenhofer Jost
Christine Helena Attenhofer Jost
PMPhilippe Müller
Philippe Müller
OBOsmund Bertel
Osmund Bertel
BNBarbara Naegeli
Barbara Naegeli
CSChristoph Scharf
Christoph Scharf
FAFranz Wolfgang Amann
Franz Wolfgang Amann
Zusammenfassung. Das Wissen um kardiovaskuläre Veränderungen im Alter und deren therapeutische Optionen ist wichtig. Es kann zur Hypertrophie des linken Ventrikels, zur diastolischen Dysfunktion, Herzklappenveränderungen und pulmonaler Hypertonie kommen. Im Alter entwickeln Patienten häufig eine arterielle Hypertonie. Bei über 100-Jährigen sind valvuläre Veränderungen häufig (Aortenstenose und Mitralinsuffizienz). Das Risiko einer koronaren Herzkrankheit beträgt 35 % für Männer und 24 % für Frauen. Im Alter sind Sinusknotendysfunktion und Vorhofflimmern gehäuft. 25 % aller Schlaganfälle sind kardiale Embolien bei Vorhofflimmern. Kardiale Interventionen bei Betagten werden zunehmend häufiger durchgeführt und beinhalten koronare kathetertechnische Revaskularisationen oder Klappeneingriffe (perkutaner Aortenklappenersatz oder MitraClip). Die optimale Therapie im Alter beinhaltet neben kardiovaskulären Interventionen auch Medikamente und eine Lebensstilmodifikation und dient vor allem der Verbesserung der Lebensqualität.
1